Oruka Therapeutics, Inc. (ORKA) on Monday announced positive interim data from its Phase 1 trial of ORKA-002.
The study, conducted in healthy volunteers, evaluated the safety and pharmacokinetics of the drug. Interim results showed a half-life of 75-80 days, supporting the potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa. ORKA-002 was well tolerated at all dose levels, with no severe or serious treatment-emergent adverse events reported.
Phase 2 studies for ORKA-002 are expected to begin in the first half of 2026 in psoriasis and the second half of 2026 in hidradenitis suppurativa.
Meanwhile, a Phase 2b study of ORKA-001 dubbed EVERLAST-B is underway with data expected in 2027.
On Friday, Oruka shares closed at $27.86, up 5.53%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.